Thiabendazole
Mechanism :
Tiabendazole, a benzimidazole derivative, has activity against most nematode worms, larval stages and ova. Its mechanism is uncertain but may inhibit fumarate-reductase system of worms, hence interfering with their source of energy. It also has some antifungal activity.
Indication :
- Cutaneous larvae migrans
- Guinea worm
- Trichiniasis
Contraindications :
Mixed worm infections involving Ascaris lumbricoides. Prophylactic treatment for enterobiasis infection.
Dosing :
Use in children 2 years and above.
Angiostrongylosis:
25 mg/kg (up to 1 g) orally 3 times a day for 3 days.
Capillariasis:
25 mg/kg (up to 3 g) orally once a day for 30 days.
Strongyloidosis:
25 mg/kg/2 times a day for 2 successive days. Alternatively, a single dose of 50 mg/kg once.
Dracunculiasis:
25 to 37.5 mg/kg (up to 1.5 g) orally 2 times a day for 3 days.
Visceral Larva Migrans (Toxocariasis):
25 mg/kg (up to 1 g) orally 2 times a day for 7 successive days. Max daily dose: 3 g.
Trichostrongylosis, Cutaneous Larva Migrans, Trichinosis:
25 mg/kg (up to 1.5 g) orally 2 times a day for 2 days.
Adverse Effect :
Dizziness; GI disturbances; pruritus, skin rashes; drowsiness, headache, fatigue, drying of mucous membrane; hyperglycaemia, visual disturbances; leukopenia; tinnitus; hepatic effects; enuresis; crystalluria; bradycardia; hypotension. Transient increase in liver test.
Potentially Fatal: Fatal Stevens-Johnson syndrome, erythema multiforme. Toxic epidermal necrolysis, liver damage.
Interaction :
Potentially Fatal: Concurrent use inhibits metabolism of theophylline and caffeine. Possible increase in anticoagulant effect with coumarins.
Hepatic Dose :
No dosage adjustments are recommended.